Receives Designation as a Best Place to Work for Disability Inclusion BURLINGTON, N.C.–(BUSINESS WIRE)–Labcorp (NYSE: LH), a leading global life sciences company, today announced that it scored 100, the highest score possible, on the 2022 Disability Equality Index® (DEI), a comprehensive benchmarking tool for measuring disability inclusion in the workplace. The DEI, a joint initiative … [Read more…]
– Tecartus® (Brexucabtagene Autoleucel) First and Only CAR T in Europe to Receive Positive CHMP Opinion to Treat Adults 26+ with r/r ALL – – If Approved, it will Address a Significant Unmet Need for a Patient Population with Limited Treatment Options – SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), today announces that … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Robotic Surgical Systems Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030” report has been added to ResearchAndMarkets.com’s offering. This report is built to visualize quantitative market trends within General Surgery Devices therapeutic area. The model discusses in detail the impact of … [Read more…]
OLD WESTBURY, N.Y.–(BUSINESS WIRE)–Grammy Award-winning and multiplatinum-selling artist Enrique Iglesias recently took center stage at the 17th annual Feinstein Summer Concert, which raised $3.6 million to support medical innovations. For more than two decades, researchers at Northwell Health’s Feinstein Institutes for Medical Research have made important discoveries in oncology, autoimmunity, neuroscience and genetics that translate … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Hemoglobin A1c Analyzer Market Research Report by Product, Technology, Type, End User, Distribution Channel, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Hemoglobin A1c Analyzer Market size was estimated at USD 344.32 million in 2021, USD 379.93 million in 2022, and … [Read more…]
VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity inducement award to Dr. Paul Moore, Zymeworks’ new Chief Scientific Officer. In accordance with the NYSE Rule, Zymeworks approved … [Read more…]
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company) announces a reduction in the exercise price of all existing warrants that were issued in the February 2022 public offering, consisting of Series A Warrants and Series B Warrants, from $0.50 per share to $0.28 per share, and entry into a … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Gastroesophageal Reflux Disease Devices Market Research Report by Product Type, Procedure Type, Device Type, Surgery Type, Route of Administration, Dosage Form, End-User, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Gastroesophageal Reflux Disease Devices Market size was estimated at USD 4,550.91 … [Read more…]
– Positive Opinion Based on HELIOS-A Phase 3 Study – – European Commission Decision Expected in September 2022 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending … [Read more…]
Approval recommended for first-line treatment of advanced melanoma patients with tumor cell PD-L1 expression < 1% Recommendation based on results from the Phase 2/3 RELATIVITY-047 trial, in which the fixed-dose combination of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab more than doubled median progression-free survival compared to nivolumab monotherapy If approved, it would … [Read more…]
